Posted in Health Economics and Outcomes Research, Health Law & Patient Safety, HealthCare IT, Healthcare Reform on December 21, 2016| Leave a Comment »
Reporter: Aviva Lev-Ari, PhD, RN
|
|||
|
|||
|
SOURCE
From: Health Affairs <communications@healthaffairs.org>
Reply-To: Health Affairs <communications@healthaffairs.org>
Date: Wednesday, December 21, 2016 at 12:30 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Health Affairs Top 10 Most-Read List – See Inside
Posted in Aortic Valve: TAVR, TAVI vs Open Heart Surgery, Cardiac and Cardiovascular Surgical Procedures, Electrophysiology, Frontiers in Cardiology and Cardiovascular Disorders, Medical Devices R&D and Inventions, Valves & Tools on December 21, 2016| Leave a Comment »
Reporter: Aviva Lev-Ari, PhD, RN
UPDATED on 8/2/2017
Medtronic wins FDA nod, CE Mark for Avalus aortic valve
AUGUST 2, 2017 BY FINK DENSFORD
BioTrace Medical, Inc., a venture backed company based in San Carlos, Calif., is dedicated to reinventing temporary pacing to improve patient outcomes and reduce hospital costs.
For more information: www.biotracemedical.com
The BioTrace Medical Tempo temporary pacing lead is designed to reduce complications and hospital length of stay
The Tempo Lead represents the first major advance in temporary pacing since the technology was introduced decades ago,” said Susheel Kodali, M.D., director of the Heart Valve Program at the Center for Interventional Vascular Therapy at Columbia University Medical Center in New York. “As a critical component of every TAVR procedure, temporary leads are integral to successful clinical outcomes for patients. I am excited about the potential of this technology and look forward to using it in my practice.”
Results of the first-in-human study of the technology will be presented at the annual Transcatheter Cardiac Therapeutics (TCT) conference in Washington, D.C. on Sunday, Oct. 30, at 10:59 a.m. eastern time in Room 209, Level 2.
“FDA clearance is an exciting milestone for BioTrace,” said Laura Dietch, CEO of BioTrace Medical. “We are pleased to bring this important innovation to the significant and growing number of patients needing better temporary pacing options to minimize risks and life-threatening complications. We look forward to launching in select U.S. centers in the coming weeks.”
For more information: www.biotracemedical.com
SOURCE
The first cases involved patients undergoing transcatheter aortic valve replacement (TAVR) procedures and were performed by James Harkness, M.D., interventional cardiologist, and Brian K. Whisenant, M.D., medical director of the Structural Heart Disease Program at Intermountain Medical Center in Salt Lake City, Utah, and Susheel Kodali, M.D., director of the Heart Valve Program at Columbia University Medical Center/New York Presbyterian Hospital.
BioTrace Medical’s Tempo Lead is for use in procedures in which
The lead is designed for secure and stable cardiac pacing with the goal of reducing complications and allowing patients to ambulate sooner after procedures.
“The Tempo Lead is designed to alleviate the risks associated with lead dislodgement and inconsistent pacing, providing a safer option for patients.”
Temporary leads are used in more than 350,000 procedures each year, a number that is growing rapidly as the population ages and TAVR becomes increasingly common. The temporary pacing lead, a small catheter with two electrodes, is placed in the right ventricle of the heart through a vein in the groin or neck. The lead is then connected to an external pacemaker allowing a physician to monitor and control a patient’s heart rate for several days.
SOURCE
Posted in CRISPR/Cas9 & Gene Editing, Interviews with Scientific Leaders, Personalized and Precision Medicine & Genomic Research on December 20, 2016| Leave a Comment »
WordCloud Image Produced by Adam Tubman
Reporter: Aviva Lev-Ari, PhD, RN
http://www.pmwcintl.com/jennifer-doudna-qa/
http://www.pmwcintl.com/2017sv/program/sessions/
http://www.pmwcintl.com/2017sv/registration/
The PMWC Luminary Award recognizes recent contributions of preeminent figures who have accelerated personalized medicine into the clinical marketplace. The PMWC Pioneer Award is given to rare individuals who presaged the advent of personalized medicine when less evolved technology and encouragement from peers existed, but still made major advances in the field.
This year, PMWC will be honoring Dr. Jennifer Doudna (UC Berkeley) with the Luminary Award for spearheading the development of the groundbreaking Crispr-Cas9 genome editing technology and Edward F. Chang for developing advanced neurophysiologic brain mapping methods. For the Pioneer Award, Dr. James Allison (MD Anderson Cancer Center) will be recognized for pioneering cancer immunotherapy through his discovery of the immune checkpoint blockade. Dr. Stephen Quake (Stanford) will receive a Pioneer Award for his prolific inventions of technologies in microfluidics and genetics that have enabled personalized medicine, drug discovery and non-invasive diagnostics.
When: January 22, 2017 at 6:30-8:30pm
Agenda: Award Ceremony Agenda
SOURCE
From: Tal Behar PMWC <talb=pmwcintl.com@mail29.atl161.mcsv.net> on behalf of Tal Behar PMWC <talb@pmwcintl.com>
Reply-To: Tal Behar PMWC <talb@pmwcintl.com>
Date: Tuesday, December 20, 2016 at 1:50 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Largest Biotech Patent Case in History Will Determine Who Owns CRISPR
|
| ||||
UPDATED – Status “Interference — Initial memorandum” – CRISPR/Cas9 – The Biotech Patent Fight of the Century: UC, Berkeley and Broad Institute @MIT
Reporter: Aviva Lev-Ari, PhD, RN
First CRISPR clinical trial gets green light from US panel – The technique’s first test in people could begin as early as the end of the year, 22 June 2016
http://www.nature.com/news/first-crispr-clinical-trial-gets-green-light-from-us-panel-1.20137
We Celebrate 5,000 Scientific Articles @pharmaceuticalintelligence.com – 2016 was a GREAT Year !!!!!
CRISPR – 124 articles on 12/20/2016
https://pharmaceuticalintelligence.com/category/crisprcas9-gene-editing/
Personalized Medicine and Precision Medicine and Genomics Research – 618 articles on 12/20/2016
Contributions to Personalized and Precision Medicine & Genomic Research: Larry H. Bernstein, MD, FCAP
http://www.amazon.com/dp/B018DHBUO6
Chapter Curators: Larry H Bernstein, MD, FCAP, Stephen J Williams, PhD and Aviva Lev-Ari, PhD, RN
Posted in CRISPR/Cas9 & Gene Editing, LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management on December 19, 2016| Leave a Comment »
Curator and Open Access Journal Editor-in-Chief: Aviva Lev-Ari, PhD, RN
http://www.amazon.com/dp/B00DINFFYC
http://www.amazon.com/dp/B018Q5MCN8
http://www.amazon.com/dp/B018PNHJ84
http://www.amazon.com/dp/B018DHBUO6
http://www.amazon.com/dp/B013RVYR2K
http://www.amazon.com/dp/B012BB0ZF0
http://www.amazon.com/dp/B019UM909A
http://www.amazon.com/dp/B019VH97LU
https://pharmaceuticalintelligence.com/biomed-e-books/
http://www.amazon.com/dp/B00DINFFYC
http://www.amazon.com/dp/B012BB0ZF0
http://www.amazon.com/dp/B013RVYR2K
http://www.amazon.com/dp/B018DHBUO6
Milestones in Physiology: Discoveries in Medicine, Genomics and Therapeutics, on Amazon.com since 12/27/2015
http://www.amazon.com/dp/B019VH97LU
http://www.amazon.com/dp/B018Q5MCN8
http://www.amazon.com/dp/B018PNHJ84
http://www.amazon.com/dp/B019UM909A
Posted in CANCER BIOLOGY & Innovations in Cancer Therapy, Cancer Genomics, Cancer Informatics, Circulating Tumor Cells (CTC), Genetics & Innovations in Treatment, Genome Biology, Genomic Testing: Methodology for Diagnosis, Liquid Biopsy: Circulating Tumor Cells in Urine and Blood, MagSifter chip, Variation in human protein-coding regions on December 19, 2016| Leave a Comment »
Reporter: Aviva Lev-Ari, PhD, RN
Norman Shumway successfully transplants a heart into 54-year-old steelworker Mike Kasperak, who survives for 14 days.
The approach that the team developed could be used to look at mutations in three or four genes, and it requires no more than 2 milliliters of blood — about half a teaspoon. The test can be completed in about five hours, the researcher said, and costs less than $30. For comparison, a single state-of-the art biopsy of lung tissue with DNA sequencing costs about $18,000 and takes as long as three weeks to furnish results. Johnson & Johnson’s CellSearch — another blood test, already approved by the FDA — costs about $900 and takes a week to deliver results.
The researchers created a system for isolating circulating tumor cells from the blood of cancer patients and reading a handful of genes from inside each tumor cell. Thus, they were able to obtain genetic information about the original cancer tumor that resides deep in the lungs without doing a biopsy, which can be dangerous for the patient.
“We are trying to make minimally invasive technology that allows us to continuously monitor one person’s health over time,” said radiology instructor Seung-min Park, PhD, a lead author of the new study, which was published online Dec. 12 in the Proceedings of the National Academy of Sciences. Park shares lead authorship of the study with former Stanford graduate students Dawson Wong, PhD, and Chin Chun Ooi.
A MagSifter chip, shown here fastened to an acrylic holder, can purify circulating tumor cells from the blood of cancer patients.
The MagSifter is an electromagnetic sieve that can be turned on and off. When the MagSifter is on, it pulls the nanoparticle-labeled CTCs from the blood sample and allows the rest of the blood to flow through the sifter. The CTCs pulled from the blood are then deposited into a flat array of tiny wells, each large enough for only one cell. Now the tumor cells are ready for genetic analysis. Each flat of 25,600 wells looks like a miniature muffin tin, with room for a lot of tiny muffins.
SOURCE
Posted in Art Exhibits on the Human Condition on December 19, 2016| Leave a Comment »
Reporter: Aviva Lev-Ari, PhD, RN
Exhibit of Note in Cambridge, MA
Digital publication for “Vision and Justice: The Art of Citizenship” (August 27, 2016–January 8, 2017, Harvard Art Museums) produced by graduate students enrolled in the course taught by Sarah Lewis, Assistant Professor in the Departments of History of Art and Architecture and African and African American Studies, Harvard University, Fall 2016.
SOURCE
http://www.harvardartmuseums.org/visit/exhibitions/5244/vision-and-justice
Posted in CANCER BIOLOGY & Innovations in Cancer Therapy on December 18, 2016| Leave a Comment »
Reporter: Aviva Lev-Ari, PhD, RN
Technion Integrated Cancer Center, a first-of-its-kind institution that brings together world-class clinical experts, a group of life science researchers led by a Nobel Prize winner, and top-level chemists, physicists and engineers to win the battle against cancer.
The TICC serves as a nexus for the Technion’s five affiliated hospitals that run clinical trials, the Rappaport Faculty of Medicine’s life sciences researchers, the Faculty of Computer Science’s innovations in processing large data sets, the Viterbi Faculty of Electrical Engineering’s and the Faculty of Physics’ development of devices for diagnosis and imaging, and the Faculty of Mathematics’ search for new, more powerful algorithms to quickly and effectively process complex data.
The power of diverse, accomplished researchers and practitioners is essential to advancing our ability to combat cancer.
“We have quite a few ideas about how to combat this disease, but translating those ideas into actual drugs is not easy. We have to determine if the drugs work by finding the right patient population because not all patients will respond to certain drugs. And we need to develop new strategies to determine who those patients are,” Ronai said. “We used to develop the same drugs to attack cancer, but we now know that cancer is complex and heterogeneous. Our drugs need to be smart enough to attack the different elements of each different type of cancer.”
SOURCE
Stephen J. Williams, PhD
in
Stephen J. Williams, PhD
20.2.1 Medical Breakthrough: Israeli Researcher Predicts Where Cancer Will Spread
Evelina Cohn Budu, PhD
20.2.2 Pancreatic Cancer at the Crossroads of Metabolism
Demet Sag, PhD, CRA, GCP
Aviva Lev-Ari, PhD, RN
Aviva Lev-Ari, PhD, RN
20.2.5 Immunity and Host Defense – A Bibliography of Research @Technion
Aviva Lev-Ari, PhD, RN
20.2.6 Host – Tumor Interactions during Cancer Therapy – Dr. Yuval Shaked’s Lab @Technion
Aviva Lev-Ari, PhD, RN
Aviva Lev-Ari, PhD, RN
Aviva Lev-Ari, PhD, RN
20.3.3 Biomarkers of Cancer detected by BreathAnalyzer – An Collaborative effort of three Universities
Aviva Lev-Ari, PhD, RN
20.3.4 Technion established the most advanced Center for Structural Biology in Israel
Aviva Lev-Ari, PhD, RN
Aviva Lev-Ari, PhD, RN
Posted in Big Data, Bio Instrumentation in Experimental Life Sciences Research, BioIT: BioInformatics, BioIT: BioInformatics, NGS, Clinical & Translational, Pharmaceutical R&D Informatics, Clinical Genomics, Cancer Informatics, Biological Networks, Biological Networks, Gene Regulation and Evolution, Biomarkers & Medical Diagnostics, Biomedical Measurement Science, Cell Biology, Cell Biology, Signaling & Cell Circuits, Chemical Genetics, Clinical Genomics, DNA repair, Gene Regulation, Gene Regulation and Evolution, Gene Therapy & Gene Editing Development, Genetics & Innovations in Treatment, Genome Biology, Genomic Testing: Methodology for Diagnosis, Variation in human protein-coding regions on December 18, 2016| Leave a Comment »
Reporter: Aviva Lev-Ari, PhD, RN
JIMB’s mission is to advance the science of measuring biology (biometrology). JIMB is pursuing fundamental research, standards development, and the translation of products that support confidence in biological measurements and reliable reuse of materials and results. JIMB is particularly focused on measurements and technologies that impact, are related to, or enabled by ongoing advances in and associated with the reading and writing of DNA.
Stanford innovators and industry entrepreneurs have joined forces with the measurement experts from NIST to create a new engine powering the bioeconomy. It’s called JIMB — “Jim Bee” — the Joint Initiative for Metrology in Biology. JIMB unites people, platforms, and projects to underpin standards-based research and innovation in biometrology.
The Genome in a Bottle Consortium is a public-private-academic consortium hosted by NIST to develop the technical infrastructure (reference standards, reference methods, and reference data) to enable translation of whole human genome sequencing to clinical practice. The priority of GIAB is authoritative characterization of human genomes for use in analytical validation and technology development, optimization, and demonstration. In 2015, NIST released the pilot genome Reference Material 8398, which is genomic DNA (NA12878) derived from a large batch of the Coriell cell line GM12878, characterized for high-confidence SNPs, indel, and homozygous reference regions (Zook, et al., Nature Biotechnology 2014).
There are four new GIAB reference materials available. With the addition of these new reference materials (RMs) to a growing collection of “measuring sticks” for gene sequencing, we can now provide laboratories with even more capability to accurately “map” DNA for genetic testing, medical diagnoses and future customized drug therapies. The new tools feature sequenced genes from individuals in two genetically diverse groups, Asians and Ashkenazic Jews; a father-mother-child trio set from Ashkenazic Jews; and four microbes commonly used in research. For more information click here. To purchase them, visit:
Data and analyses are publicly available (GIAB GitHub). A description of data generated by GIAB is published here. To standardize best practices for using GIAB genomes for benchmarking, we are working with the Global Alliance for Genomics and Health Benchmarking Team (benchmarking tools).
High-confidence small variant and homozygous reference calls are available for NA12878, the Ashkenazim trio, and the Chinese son with respect to GRCh37. Preliminary high-confidence calls with respect to GRCh38 are also available for NA12878. The latest version of these calls is under the latest directory for each genome on the GIAB FTP.
The consortium was initiated in a set of meetings in 2011 and 2012, and the consortium holds open, public workshops in January at Stanford University in Palo Alto, CA and in August/September at NIST in Gaithersburg, MD. Slides from workshops and conferences are available online. The consortium is open and welcomes new participants.
Stanford innovators and industry entrepreneurs have joined forces with the measurement experts from NIST to create a new engine powering the bioeconomy. It’s called JIMB — “Jim Bee” — the Joint Initiative for Metrology in Biology. JIMB unites people, platforms, and projects to underpin standards-based research and innovation in biometrology.
JIMB’s mission is to motivate standards-based measurement innovation to facilitate translation of basic science and technology development breakthroughs in genomics and synthetic biology.
By advancing biometrology, JIMB will push the boundaries of discovery science, accelerate technology development and dissemination, and generate reusable resources.
SOURCE
VIEW VIDEO
https://player.vimeo.com/video/184956195?wmode=opaque&api=1″,”url”:”https://vimeo.com/184956195″,”width”:640,”height”:360,”providerName”:”Vimeo”,”thumbnailUrl”:”https://i.vimeocdn.com/video/594555038_640.jpg”,”resolvedBy”:”vimeo”}” data-block-type=”32″>
“Genome in a Bottle”: NIST’s new metrics for Clinical Human Genome Sequencing
Reporter: Aviva Lev-Ari, PhD, RN
2012pharmaceutical
sjwilliamspa